Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP and CFO | February 18, 2025 | February 19, 2025 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
| WATERS CORP /DE/WAT · Entity 3080 | Director | February 25, 2026 | February 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 18, 2025 · Filed February 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 225,808 |
Ending reported balance
After 2025-02-19 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2025-02-18 · Sale · Disposed 2,900 · Balance 247,248 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2025-02-18 · Sale · Disposed 14,630 · Balance 232,618 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2025-02-19 · Exercise / conversion · Acquired 18,533 · Balance 251,151 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 4 · 2025-02-19 · Exercise / conversion · Acquired 16,865 · Balance 268,016 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 5 · 2025-02-19 · Exercise / conversion · Acquired 15,642 · Balance 283,658 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 6 · 2025-02-19 · Exercise / conversion · Acquired 9,483 · Balance 293,141 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Row 7 · 2025-02-19 · Sale · Disposed 67,333 · Balance 225,808 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.09 · Expires 2028-02-15 | Direct | 31,285 |
Reported balance
After 2025-02-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-19 · Exercise / conversion · Disposed 15,642 · Balance 31,285 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.12 · Expires 2029-02-21 | Direct | 37,934 |
Reported balance
After 2025-02-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-19 · Exercise / conversion · Disposed 9,483 · Balance 37,934 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F6: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.26 · Expires 2026-02-22 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-19 · Exercise / conversion · Disposed 16,865 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F7: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.55 · Expires 2027-02-28 | Direct | 37,067 |
Reported balance
After 2025-02-19 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-02-19 · Exercise / conversion · Disposed 18,533 · Balance 37,067 F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F8: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.35 to $104.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.37 to $105.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
F6: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
F7: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
F8: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,371 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 404 · Balance 1,371 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 681 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 681 · Balance 681 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
WATERS CORP /DE/
Report date February 25, 2026 · Filed February 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,355 |
Reported balance
After 2026-02-25 transaction · row 1
1 source rowRow 1 · 2026-02-25 · Grant · Acquired 23 · Balance 1,355 F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $319.44 · Expires 2036-02-25 | Direct | 57 |
Reported balance
After 2026-02-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-25 · Grant · Acquired 57 · Balance 57 F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock subject to restrictions that lapse with respect to 100% of the shares on February 9, 2027.
F2: All of the shares of common stock underlying this stock option will vest and become exercisable on February 9, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Nuance Communications, Inc.
Report date March 04, 2022 · Filed March 04, 2022
Section 16 reporting ended · disclosed 2022-03-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-03-04 · Disposition to issuer · Disposed 4,519 · Balance 53,492 F1: Represents shares of common stock (each, a Company Share), par value $0.001 per share, of Nuance Communications, Inc. (the Company) underlying restricted stock units (Company RSUs). Pursuant to the Agreement and Plan of Merger, dated as of April 11, 2021, by and among the Company, Microsoft Corporation and Big Sky Merger Sub Inc. (Merger Sub), each outstanding Company RSU award was canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (i) $56.00 multiplied by (ii) the number of Company Shares underlying the Company RSU award. Row 2 · 2022-03-04 · Disposition to issuer · Disposed 53,492 · Balance 0 F2: On March 4, 2022, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the Merger), and each Company Share issued and outstanding at the effective time of the Merger was converted into the right to receive $56.00 in cash without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock (each, a Company Share), par value $0.001 per share, of Nuance Communications, Inc. (the Company) underlying restricted stock units (Company RSUs). Pursuant to the Agreement and Plan of Merger, dated as of April 11, 2021, by and among the Company, Microsoft Corporation and Big Sky Merger Sub Inc. (Merger Sub), each outstanding Company RSU award was canceled and converted into the right to receive an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (i) $56.00 multiplied by (ii) the number of Company Shares underlying the Company RSU award.
F2: On March 4, 2022, pursuant to the Merger Agreement, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the Merger), and each Company Share issued and outstanding at the effective time of the Merger was converted into the right to receive $56.00 in cash without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 18, 2020 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 16,781 | $42.31 | $710,004.11 |
DisclosureSEC source: 0001225208-20-002601 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,430 Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 36,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002601 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,211 F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 13, 2020 Filed Feb 13, 2020 22:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,463 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-20-002210 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,463 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| February 13, 2020 Filed Feb 13, 2020 22:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 20,463 | $42.03 | $860,041.47 |
DisclosureSEC source: 0001225208-20-002210 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,247 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $41.82 to $42.18, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 13, 2020 22:17 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 20,463 | $7.41 | $151,630.83 |
DisclosureSEC source: 0001225208-20-002210 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 21,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000291 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,865 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F1 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F1 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 6,578 | $45.22 | $297,457.16 |
DisclosureSEC source: 0001225208-20-000291 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,247 Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:18 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 21,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000291 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 16:11 UTC | Nuance Communications, Inc. NUAN · Entity 12406 | GrantCommon Stock | 14,050 | $0.00 | $14.05 |
DisclosureSEC source: 0001595612-20-000002 · edgardoc.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,822 F1 · shares: Shares are subject to a Restricted Stock Purchase Agreement and were issued pursuant to the 1995 Directors' Stock Plan. Shares will vest on the first anniversary of the date of grant. F2 · balance_after: On October 1, 2019, Nuance Communications, Inc., the Issuer, announced the completion of the spin off of its Auto division. In connection with the spin off, outstanding Issuer restricted stock units were adjusted such that each restricted stock unit award was converted into 1.16667 restricted stock units. The table above reflects the number of restricted stock units, as adjusted for the spin off. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,462 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-013151 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,463 Underlying: Common Stock · 20,462 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 20,462 | $39.44 | $807,039.70 |
DisclosureSEC source: 0001225208-19-013151 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,960 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.05 to $39.85, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 20,462 | $7.41 | $151,623.42 |
DisclosureSEC source: 0001225208-19-013151 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 20:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 46,360 | $40.02 | $1,855,545.09 |
DisclosureSEC source: 0001225208-19-005357 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,960 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.875 to $40.23, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 64,223 | $40.84 | $2,622,552.63 |
DisclosureSEC source: 0001225208-19-004586 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,320 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.70 to $41.00, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004341 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,443 Underlying: Common Stock · 4,480 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,992 | $40.12 | $79,919.04 |
DisclosureSEC source: 0001225208-19-004341 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,543 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 21:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004341 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,734 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,549 | $40.52 | $103,285.48 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · nonDerivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,055 Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · nonDerivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 5,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,365 Underlying: Common Stock · 5,365 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,385 | $40.52 | $96,640.20 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,870 Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 5,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,588 Underlying: Common Stock · 5,794 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,576 | $40.52 | $104,379.52 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,890 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:33 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 5,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003720 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 47,417 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003560 · doc4.xml · derivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,417 Underlying: Common Stock · 47,417 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 14,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003560 · doc4.xml · derivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,643 Underlying: Common Stock · 14,643 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 24,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003434 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,479 Underlying: Common Stock · 24,479 shares Expires 2020-12-31 F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F3 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F3 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F3 · balance_after: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 25,753 | $40.11 | $1,032,952.83 |
DisclosureSEC source: 0001225208-19-003434 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,672 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 57,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003434 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,425 F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2018 and subject to the completion of the concurrent three-year individual service period. On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002978 · doc4.xml · derivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,612 Underlying: Common Stock · 4,152 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,846 | $40.01 | $73,858.46 |
DisclosureSEC source: 0001225208-19-002978 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,489 Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,152 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002978 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:14 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 22,438 | $39.57 | $887,912.05 |
DisclosureSEC source: 0001225208-19-002978 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,183 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.42 to $39.66, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 33,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000434 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,081 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 10,643 | $35.34 | $376,123.62 |
DisclosureSEC source: 0001225208-19-000434 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,621 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 33,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000434 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 17:13 UTC | Nuance Communications, Inc. NUAN · Entity 12406 | GrantCommon Stock | 30,395 | $0.00 | $30.40 |
DisclosureSEC source: 0001595612-18-000005 · edgardoc.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,395 F1 · kind: Shares are subject to a Restricted Stock Purchase Agreement and were issued pursuant to the 1995 Directors' Stock Plan. One-third of the shares vest on the first, second and third anniversaries of the date of grant. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,572 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · derivative · entry 11 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,144 Underlying: Common Stock · 7,572 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F7 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,422 | $0.00 Strike: $7.16 | $0.00 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · derivative · entry 10 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,846 Underlying: Common Stock · 12,422 shares Expires 2021-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 28, 2012, the first anniversary of the date of grant. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,093 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,187 Underlying: Common Stock · 6,093 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,661 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,984 Underlying: Common Stock · 13,661 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,461 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,925 Underlying: Common Stock · 20,461 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 60,209 | $27.87 | $1,678,012.79 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · nonDerivative · entry 6 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,183 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $27.68 to $28.02, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 6,093 | $6.28 | $38,264.04 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · nonDerivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 7,572 | $7.39 | $55,957.08 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 12,422 | $7.16 | $88,941.52 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 13,661 | $13.08 | $178,685.88 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 19, 2018 Filed Mar 20, 2018 22:47 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 20,461 | $7.41 | $151,616.01 |
DisclosureSEC source: 0001225208-18-006511 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.